Sensydia has raised nearly $8m in a financing round for advancing its cardiac performance system (CPS) platform.
Led by Florida-based Orlando Health Ventures, the financing round saw participation from Frontier Venture Capital, Colle Capital and other investors.
Go deeper with GlobalData
Sensydia intends to use the funds to prepare for the commercialisation of CPS, the next-generation haemodynamic monitoring platform.
Sensydia president and CEO Anthony Arnold said: “We are thrilled to have the support of investors who share our vision for transforming heart failure management.
“This funding will enable us to accelerate our march to commercialisation by expanding development and operations for our CPS platform.”
The CPS platform has been designed to offer quick, safe and non-invasive cardiac performance assessment, which can be undertaken anywhere, avoiding the need to visit a catheterisation lab.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataUsing AI algorithms and ultra-sensitive biosensors, the platform provides multiple, non-invasive measurements, including cardiac output, pulmonary capillary wedge pressure, ejection fraction and pulmonary artery pressure, in a handheld device.
It is suitable for the operating room, ICU, clinic, ER, office, as well as home care settings.
The company stated that the platform uses waveform machine learning methods which have been trained to gold-standard measurements obtained from in-hospital catheterisation lab data.
In January last year, the CPS received Breakthrough Device Designation from the US Food and Drug Administration.
Orlando Health Heart and Vascular Institute president Farhan Khawaja said: “Non-invasive and real-time cardiac function measures will lead to early diagnosis and personalised care for heart disease.
“This technology has the potential to vastly improve patient lives by enabling faster and more affordable disease management, moving healthcare from the hospital setting into the patient’s home.”
Simultaneously, the company has announced that Orlando Health chief administrative officer Erick Hawkins will join its board of directors.
